Alzamend Neuro (ALZN) News Today $1.11 -0.14 (-11.20%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpoDecember 19 at 4:50 AM | finance.yahoo.comShort Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Declines By 7.9%December 18, 2024 | americanbankingnews.comAscendiant Capital Markets Issues Pessimistic Forecast for Alzamend Neuro (NASDAQ:ALZN) Stock PriceDecember 17, 2024 | americanbankingnews.comAlzamend Neuro Reports Strong Financial Results and Clinical Program UpdatesDecember 15, 2024 | americanbankingnews.comAlzamend Neuro says net cash gained by financing activity $8.3MDecember 12, 2024 | markets.businessinsider.comEXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug PotentialNovember 19, 2024 | finance.yahoo.comAlzamend Neuro regains Nasdaq compliance with equity ruleOctober 17, 2024 | uk.investing.comAlzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer'sOctober 16, 2024 | stockhouse.comEXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer'sOctober 16, 2024 | msn.comAlzamend Neuro Regains Compliance with Nasdaq Listing StandardsOctober 15, 2024 | finance.yahoo.comAlzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare ConferenceOctober 10, 2024 | finance.yahoo.comAlzamend Neuro Issues Letter to StockholdersAugust 26, 2024 | finance.yahoo.comAlzamend Neuro Shares Rise on Partnership for PTSD Treatment Mid-Stage StudyAugust 20, 2024 | marketwatch.comAlzamend Neuro (NASDAQ:ALZN) Stock, Short Interest ReportAugust 20, 2024 | benzinga.comAlzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News SummaryAugust 20, 2024 | benzinga.comAlzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: DetailsAugust 20, 2024 | msn.comAlzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive DisorderAugust 12, 2024 | theglobeandmail.comAlzamend Neuro partners with Mass General for Phase II trialAugust 8, 2024 | uk.investing.comAlzamend Neuro director buys shares worth $93August 3, 2024 | investing.comAlzamend Neuro regains Nasdaq compliance with bid priceAugust 2, 2024 | investing.comALZN Alzamend Neuro, Inc.July 19, 2024 | seekingalpha.comAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionMay 9, 2024 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred SharesMay 9, 2024 | finance.yahoo.comAlzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares SlideMay 7, 2024 | msn.comAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramMay 7, 2024 | finance.yahoo.comAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are BuyingApril 24, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42April 17, 2024 | msn.comALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024March 26, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50February 24, 2024 | msn.comMaxim gets more bearish on Alzamend Neuro, downgrades sharesFebruary 13, 2024 | realmoney.thestreet.comAlzamend Neuro Risks Nasdaq Delisting Over Price DeficiencyFebruary 3, 2024 | msn.comBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market PotentialDecember 19, 2023 | markets.businessinsider.comALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024December 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024December 18, 2023 | msn.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsDecember 11, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next YearDecember 11, 2023 | finance.yahoo.comAlzamend Neuro Gets FDA Approval for Trial of Depression TreatmentNovember 20, 2023 | marketwatch.comEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder StudyNovember 20, 2023 | msn.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNovember 20, 2023 | finance.yahoo.comAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNovember 16, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug CandidateNovember 13, 2023 | msn.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001November 13, 2023 | finance.yahoo.comAlzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38November 2, 2023 | msn.comWhy Alzamend Neuro (ALZN) Stock Is Nosediving TodayOctober 30, 2023 | benzinga.comAlzamend Neuro Announces Reverse Stock SplitOctober 30, 2023 | finance.yahoo.comAlzamend Neuro, Inc. (9ZT0.F)October 25, 2023 | finance.yahoo.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001October 23, 2023 | businesswire.comEXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar DisorderOctober 2, 2023 | msn.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOctober 2, 2023 | finance.yahoo.comAlzamend Neuro CFO Katzoff buys 53K sharesSeptember 27, 2023 | seekingalpha.com Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast. Click here for the ticker >>> ALZN Media Mentions By Week ALZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALZN News Sentiment▼0.050.60▲Average Medical News Sentiment ALZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALZN Articles This Week▼40▲ALZN Articles Average Week Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Citius Pharmaceuticals News Today Finch Therapeutics Group News Today Cognition Therapeutics News Today Cadrenal Therapeutics News Today MIRA Pharmaceuticals News Today Unity Biotechnology News Today Carisma Therapeutics News Today Pieris Pharmaceuticals News Today Aprea Therapeutics News Today Synlogic News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALZN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
